Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - July 2014

The National Institute of Health and Care Excellence (NICE) has published new guidance for the month of July 2014. This month there is one clinical guideline that impacts upon primary care.

The Lipid Modification guideline offers evidence-based advice on the care and treatment of people at risk of cardiovascular disease and people who have had previous cardiovascular disease. It includes new and updated recommendations on risk assessment, lifestyle modifications and the use of lipid-lowering drugs. In particular the following changes are noted:

  • The QRISK2 risk assessment tool is recommended to assess CVD risk
  • Lipid-lowering drugs are now recommended in people with a QRISK of 10% when the management of all other modifiable CVD risk factors has been optimised
  • Atorvstatin 20mg daily is the recommended treatment for primary prevention and 80mg daily is recommended for secondary prevention

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - July 2014' on Email Share 'NICE Guidance - July 2014' on Delicious Share 'NICE Guidance - July 2014' on Digg Share 'NICE Guidance - July 2014' on Facebook Share 'NICE Guidance - July 2014' on Google+ Share 'NICE Guidance - July 2014' on reddit Share 'NICE Guidance - July 2014' on StumbleUpon Share 'NICE Guidance - July 2014' on Twitter

atomic-wealth

No Comments to “NICE Guidance - July 2014”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,213 spam comments.

atomic-wealth
fond-illness
summer